| P50 | author | Francisco J. Quintana | Q88364866 |
| | Howard L. Weiner | Q20985921 |
| | Tanuja Chitnis | Q30353265 |
| P2093 | author name string | Rohit Bakshi | |
| | Brian C Healy | |
| | Christopher Severson | |
| | Gloria Kim | |
| | James M Stankiewicz | |
| | Lynn Stazzone | |
| | Maria K Houtchens | |
| | Shahamat Tauhid | |
| | Fawad Yousuf | |
| | Renxin Chu | |
| | Dorlan Kimbrough | |
| P2860 | cites work | Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. | Q50550817 |
| | A longitudinal MRI study of cervical cord atrophy in multiple sclerosis. | Q50922131 |
| | Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. | Q51973145 |
| | Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. | Q51993019 |
| | Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 |
| | Defining the clinical course of multiple sclerosis: the 2013 revisions | Q22241654 |
| | The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects | Q26770815 |
| | Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis | Q28080754 |
| | Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis | Q28545984 |
| | Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial | Q29012779 |
| | Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis | Q30510541 |
| | Thalamic atrophy is associated with development of clinically definite multiple sclerosis | Q30619701 |
| | Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging | Q30835804 |
| | Thalamus pathology in multiple sclerosis: from biology to clinical application. | Q30871067 |
| | Role of MRI in multiple sclerosis I: inflammation and lesions | Q30892336 |
| | Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis | Q31027953 |
| | Iron in chronic brain disorders: imaging and neurotherapeutic implications | Q31117154 |
| | Imaging outcomes for neuroprotection and repair in multiple sclerosis trials | Q33457990 |
| | The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis | Q33698702 |
| | An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. | Q34197065 |
| | Learning robust cortico-cortical associations with the basal ganglia: an integrative review | Q34451377 |
| | Basal ganglia circuit loops, dopamine and motivation: A review and enquiry. | Q34473463 |
| | Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. | Q34594049 |
| | Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial | Q34675482 |
| | Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. | Q34986741 |
| | Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives | Q35182733 |
| | Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors | Q35535764 |
| | Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology | Q35843537 |
| | The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis | Q36183159 |
| | Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis | Q36265339 |
| | Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis | Q36584411 |
| | A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study | Q36617521 |
| | A New MRI Masking Technique Based on Multi-Atlas Brain Segmentation in Controls and Schizophrenia: A Rapid and Viable Alternative to Manual Masking | Q37708104 |
| | Local and afferent synaptic pathways in the striatal microcircuitry | Q38519415 |
| | Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis | Q40441693 |
| | Longitudinal assessment of subcortical gray matter volume, cortical thickness, and white matter integrity in HIV-positive patients. | Q40799745 |
| | Increased deep gray matter iron is present in clinically isolated syndromes | Q41067352 |
| | Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis | Q43806089 |
| | Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years | Q46466612 |
| | Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study | Q46952197 |
| | Serial MRI in multiple sclerosis: a prospective pilot study of lesion load, whole brain volume and thalamic atrophy | Q48090684 |
| | Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis | Q48204718 |
| | Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study | Q48365884 |
| | Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. | Q48447258 |
| | Brain atrophy in radiologically isolated syndromes | Q48488406 |
| | MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability | Q48550106 |
| | EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis | Q48565199 |
| | White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. | Q48707884 |
| | The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction | Q48851450 |
| | Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study | Q48960941 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P304 | page(s) | 971-980 | |
| P577 | publication date | 2017-01-19 | |
| P1433 | published in | International Journal of Neuroscience | Q6051511 |
| P1476 | title | Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis | |
| P478 | volume | 127 | |